Pancreatic biomarkers: Could they be the answer?
Lamarca, Angela Feliu, J
Lamarca, Angela
Feliu, J
Citations
Altmetric:
Abstract
Pancreatic ductal adenocarcinoma (PDA) is known for its poor prognosis. Most of the patients are diagnosed with advanced stages, when no curative treatment is available. Currently, despite extensive clinical research on PDA, the median overall survival remains short. Diagnosis delay and primary chemo-resistance due to its intrinsic biological nature may explain the challenges to improve our results. Our knowledge about the molecular biology of PDA has exponentially increased during the last decades and its use for the development of biomarkers could help to reach better results in the clinical setting. These biomarkers could be the clue for the improvement in PDA clinical research by earlier detection strategies with diagnostic biomarkers, and by an individualization of treatment approach with prognostic and predictive biomarkers. This review summarizes the current knowledge about the molecular biology of PDA and the status of the most important prognostic and predictive biomarkers.
Authors
Description
Date
2014-06-28
Publisher
Collections
Keywords
Type
Article
Citation
Pancreatic biomarkers: Could they be the answer? 2014, 20 (24):7819-7829 World J Gastroenterol